Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Up to $20.17

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating)’s share price gapped up before the market opened on Thursday . The stock had previously closed at $20.17, but opened at $21.23. Zentalis Pharmaceuticals shares last traded at $21.23, with a volume of 1 shares.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on ZNTL shares. Oppenheimer decreased their price objective on shares of Zentalis Pharmaceuticals from $80.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, November 10th. Guggenheim decreased their price target on shares of Zentalis Pharmaceuticals from $55.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday, November 11th. SVB Leerink decreased their price target on shares of Zentalis Pharmaceuticals from $42.00 to $27.00 and set an “outperform” rating on the stock in a research note on Thursday, November 10th. UBS Group decreased their price target on shares of Zentalis Pharmaceuticals to $52.00 in a research note on Monday, November 21st. Finally, Wedbush decreased their price target on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an “outperform” rating on the stock in a research note on Monday, November 14th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $46.56.

Zentalis Pharmaceuticals Stock Up 4.7 %

The company’s fifty day simple moving average is $20.56 and its two-hundred day simple moving average is $24.28. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -5.28 and a beta of 1.77.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 10,000 shares of the stock in a transaction on Thursday, January 5th. The shares were sold at an average price of $21.02, for a total value of $210,200.00. Following the sale, the president now directly owns 362,011 shares in the company, valued at $7,609,471.22. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last three months, insiders have sold 47,500 shares of company stock worth $1,084,575. Company insiders own 19.90% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in ZNTL. JPMorgan Chase & Co. raised its holdings in shares of Zentalis Pharmaceuticals by 284.2% during the first quarter. JPMorgan Chase & Co. now owns 105,579 shares of the company’s stock worth $4,871,000 after acquiring an additional 78,102 shares during the period. US Bancorp DE raised its holdings in shares of Zentalis Pharmaceuticals by 378.9% during the first quarter. US Bancorp DE now owns 1,451 shares of the company’s stock worth $67,000 after acquiring an additional 1,148 shares during the period. MetLife Investment Management LLC raised its holdings in shares of Zentalis Pharmaceuticals by 57.0% during the first quarter. MetLife Investment Management LLC now owns 19,665 shares of the company’s stock worth $907,000 after acquiring an additional 7,139 shares during the period. Rhumbline Advisers raised its holdings in shares of Zentalis Pharmaceuticals by 7.0% during the first quarter. Rhumbline Advisers now owns 37,923 shares of the company’s stock worth $1,750,000 after acquiring an additional 2,475 shares during the period. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Zentalis Pharmaceuticals during the first quarter worth $4,221,000.

About Zentalis Pharmaceuticals

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.